Meningitis vaccine clinical pharmacology: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Meningitis vaccine}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Clinical Pharmacology== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | publisher = | date = | accessdate = }}</ref> | ===Mechanism of Action=== | ||
[[Neisseria meningitidis]] is a [[gram-negative diplococcus]] that causes life-threatening invasive disease such as[[ meningitis]] and[[ sepsis]]. Globally, 5 serogroups, A, B, C, Y and W-135 cause almost all invasive meningococcal infections. The presence of serum bactericidal antibodies protects against invasive meningococcal disease 16. Vaccination with MENVEO leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 15:11, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Clinical Pharmacology
Mechanism of Action
Neisseria meningitidis is a gram-negative diplococcus that causes life-threatening invasive disease such asmeningitis andsepsis. Globally, 5 serogroups, A, B, C, Y and W-135 cause almost all invasive meningococcal infections. The presence of serum bactericidal antibodies protects against invasive meningococcal disease 16. Vaccination with MENVEO leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.[1]
References
- ↑ "http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a". External link in
|title=(help)
Adapted from the FDA Package Insert.